Online inquiry

IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2627MR)

This product GTTS-WQ2627MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets IL2RB gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001290023.2; NM_001258214.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3594; 3595
UniProt ID P42701; Q99665
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2627MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15488MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ4915MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ3433MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ351MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ14803MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ4424MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ1731MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ2532MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW